Abstract：
Good adherence by physicians to treatment guidelines for type II diabetes mellitus (T2DM) could improve therapy outcome for patients. In this retrospective, cross-sectional study, we assessed physicians\' adherence to evidence-based guidelines for T2DM management in adult patients (aged ≥18 years) with either confirmed atherosclerotic cardiovascular disease (ASCVD) or those at high risk of developing ASCVD at the Thumbay Academic Health Center, United Arab Emirates (UAE).
Relevant data was obtained from patients\' medical records, assessed, and compared based on the 2018 diabetes guidelines of the American Diabetes Association and European Association for the Study of Diabetes.
A total of 218 patients (186 males and 32 females) were included in the analysis. Of these, 122 were prescribed either sodium-glucose co-transporter-2(SGLT2) inhibitors or glucagon-like peptide 1 (GLP-1) receptor agonists and 34 were prescribed both. The overall adherence to the guidelines was 56%, which was significantly influenced by body mass index (BMI), hemoglobin A1c (HbA1c) levels, and estimated average glucose (eAG).
Adherence to guidelines was significantly high when treating patients with elevated levels of HbA1c and eAG, suggesting that physicians are more likely to prescribe SGLT2 inhibitors or/and GLP-1 receptor agonists to such patients. Physicians\' adherence to guidelines was significantly correlated with patients\' BMI and the levels of HbA1c and eAG. To the best of our knowledge, this is the first study conducted on diabetes and its risk factors in UAE.
Relevant data was obtained from patients\' medical records, assessed, and compared based on the 2018 diabetes guidelines of the American Diabetes Association and European Association for the Study of Diabetes.
A total of 218 patients (186 males and 32 females) were included in the analysis. Of these, 122 were prescribed either sodium-glucose co-transporter-2(SGLT2) inhibitors or glucagon-like peptide 1 (GLP-1) receptor agonists and 34 were prescribed both. The overall adherence to the guidelines was 56%, which was significantly influenced by body mass index (BMI), hemoglobin A1c (HbA1c) levels, and estimated average glucose (eAG).
Adherence to guidelines was significantly high when treating patients with elevated levels of HbA1c and eAG, suggesting that physicians are more likely to prescribe SGLT2 inhibitors or/and GLP-1 receptor agonists to such patients. Physicians\' adherence to guidelines was significantly correlated with patients\' BMI and the levels of HbA1c and eAG. To the best of our knowledge, this is the first study conducted on diabetes and its risk factors in UAE.
摘要：
医生对II型糖尿病（T2DM）治疗指南的良好依从性可以改善患者的治疗结果。在这次回顾中,横断面研究，我们在Thumbay学术健康中心评估了患有动脉粥样硬化性心血管疾病（ASCVD）或发展为ASCVD高风险的成年患者（年龄≥18岁）对T2DM治疗循证指南的依从性。阿拉伯联合酋长国（阿联酋）。
相关数据来自患者的医疗记录，评估,并根据美国糖尿病协会和欧洲糖尿病研究协会的2018年糖尿病指南进行了比较。
共有218名患者（186名男性和32名女性）被纳入分析。其中,122种被处方为钠-葡萄糖共转运蛋白2（SGLT2）抑制剂或胰高血糖素样肽1（GLP-1）受体激动剂，34种被处方为两者。对指南的总体依从性为56%,这受到体重指数(BMI)的显著影响，血红蛋白A1c（HbA1c）水平，和估计平均葡萄糖（eAG）。
在治疗HbA1c和eAG水平升高的患者时，对指南的依从性明显较高，提示内科医生更有可能给这类患者开SGLT2抑制剂或/和GLP-1受体激动剂.医师对指南的依从性与患者的BMI以及HbA1c和eAG水平显着相关。据我们所知,这是阿联酋首次针对糖尿病及其危险因素进行的研究.
相关数据来自患者的医疗记录，评估,并根据美国糖尿病协会和欧洲糖尿病研究协会的2018年糖尿病指南进行了比较。
共有218名患者（186名男性和32名女性）被纳入分析。其中,122种被处方为钠-葡萄糖共转运蛋白2（SGLT2）抑制剂或胰高血糖素样肽1（GLP-1）受体激动剂，34种被处方为两者。对指南的总体依从性为56%,这受到体重指数(BMI)的显著影响，血红蛋白A1c（HbA1c）水平，和估计平均葡萄糖（eAG）。
在治疗HbA1c和eAG水平升高的患者时，对指南的依从性明显较高，提示内科医生更有可能给这类患者开SGLT2抑制剂或/和GLP-1受体激动剂.医师对指南的依从性与患者的BMI以及HbA1c和eAG水平显着相关。据我们所知,这是阿联酋首次针对糖尿病及其危险因素进行的研究.
